Journal
NEURO-ONCOLOGY
Volume 14, Issue 6, Pages 761-767Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nos065
Keywords
oligoastrocytoma; oligodendroglioma; PCV; temozolomide; 1p19q
Categories
Funding
- Merck Co.
- Sigma Tau Pharmaceuticals
- Keryx Biopharmaceuticals
- Astra Zeneca
- Genentech/Roche
- Roche
- National Brain Tumor Society
- Susan Smith Klein Brain Tumor Fund
- Daniel E. Rich Fund
Ask authors/readers for more resources
Anaplastic oligodendroglial tumors are rare neoplasms with no standard approach to treatment. We sought to determine patterns of treatment delivered over time and identify clinical correlates of specific strategies using an international retrospective cohort of 1013 patients diagnosed from 1981-2007. Prior to 1990, most patients received radiotherapy (RI) alone as initial postoperative treatment. After 1990, approximately 50% of patients received both RI and chemotherapy (CT) sequentially and/or concurrently. Treatment with RI alone became significantly less common (67% in 1980-1984 vs 5% in 2005-2007, P < .0001). CT alone was more frequently administered in later years (0% in 1980-1984 vs 38% in 2005-2007; P < .0001), especially in patients with 1p19q codeleted tumors (57% of codeleted vs 4% with no deletion in 2005-2007; P < .0001). Temozolomide replaced the combination of procarbazine, lomustine, and vincristine (PCV) among patients who received CT alone or with RI (87% vs 2% in 2005-2007). In the most recent time period, patients with 1p19q codeleted tumors were significantly more likely to receive CT alone (with temozolomide), whereas RI with temozolomide was a significantly more common treatment strategy than either CT or RI alone in cases with no deletion (P < .0001). In a multivariate polytomous logistic regression model, the following were significantly associated with type of treatment delivered: date (5-year interval) of diagnosis (P < .0001), 1p19q codeletion (P < .0001), pure anaplastic oligodendroglioma histology (P < .01), and frontal lobe predominance (P < .05). Limited level 1 evidence is currently available to guide treatment decisions, and ongoing phase III trials will be critical to understanding the optimal therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available